01177 SINO BIOPHARM
- 3.120
- +0.060+1.96%
SINO BIOPHARM News
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
China Biopharmaceutical (1177.HK) Follow-up Review: Self-developed New Drugs Accelerate Implementation, Equity Incentives Promote Long-term Development
Maintain the “gain” rating. Taking into account the intensive harvesting period of the company's multiple pipelines, the adjusted EPS forecast for 20242026 was 0.15/0.18/0.21 yuan (originally 0.15/0.18/0.20 yuan). Maintain* Increase holdings
Sino Biopharmaceutical's Novel Lung Cancer Drug Approved in China; Shares Up 5%
Sino Biopharmaceutical (HKG:1177) said its category 1 innovative drug Benmelstobart Injection obtained approval for marketing from China's National Medical Products Administration (NMPA) as a first-li
Changes in Hong Kong stocks | Zhongsheng Pharmaceutical (01177) is now up more than 6%, and its lung cancer drugs have been approved for listing. 52 research results will be announced by ASCO in '24
Zhongsheng Pharmaceutical (01177) is now up nearly 6%. As of press release, it is up 6.19% to HK$3.09, with a turnover of HK$159 million.
China Biopharmaceutical (01177.HK): Class 1 innovative bemosubicumab injection “Benmelstobart (TQB2450)” combined with anlotinib hydrochloride capsules for first-line treatment of small cell lung cancer was approved for marketing
Gelonghui, May 9 | China Biopharmaceutical (01177.HK) announced that the Group's self-developed, innovative bemosubidumab injection “Benmelstobart (TQB2450)” (trade name: Andevil) has been approved for marketing by the China National Drug Administration and used in combination with anlotinib hydrochloride capsules, carboplatin, and etopogan for first-line treatment of patients with extensive small cell lung cancer (ES-SCLC). Bemosubimab is a humanized PD-L1 monoclonal antibody independently developed by the Group. It can block PD-1 and B7 on the surface of PD-L1 and T cells
China Biopharmaceutical (01177.HK): Chia Tai Tianqing implements share incentive plan
Gelonghui, May 7, 丨 China Biopharmaceutical (01177.HK) announced that the board of directors decided to pass the company's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (“Chia Tai Tianqing”), to implement a share incentive plan to stimulate core talents who will play an important role in the future operation and development of Zhengda Tianqing. This is the first time since the Group went public that a share incentive plan has been implemented in Zhengda Tianqing. The purpose of the share incentive plan is to further establish and improve the benefit-sharing mechanism between Chia Tai Tianqing and employees, mobilize employees' enthusiasm and creativity, enhance employee cohesion and Chia Tai Tianqing's competitiveness, and promote the long-term, sustainable and healthy development of Chia Tai Tianqing
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Express News | China Biotech's Wuhan Biological quadrivalent influenza vaccine was approved for registration in the UAE and won the bid
Express News | China Biopharmaceutical: Class 1 innovative drug anectinib fumarate capsules “UNECRITINIB (TQ-B3101)” approved for marketing
Anectinib fumarate capsules, a Class 1 innovative drug independently developed by China Biopharmaceutical (01177), were approved for marketing
China Biopharmaceutical (01177) announced that the group's self-developed Class 1 innovative drug anectinil fumarate capsules “U...
Hong Kong Stock Concept Tracking | ASCO Research Title Publishers Focus on Opportunities in the Domestic Innovative Drug Industry (with concept stocks)
After years of cultivation, domestically produced innovative drugs have reached the initial stage of producing results, and ASCO's participation has further increased in '24
Express News | China Biopharmaceutical: Amberni, the first domestically produced ROS1-positive non-small cell lung cancer target drug, was approved for marketing
China Biopharmaceutical (01177): 52 research results will be announced at the 2024 ASCO Annual Meeting
Zhitong Finance App News, China Biopharmaceutical (01177) announced that the Group's Class 1 innovative drugs “anlotinib (small molecule multi-target receptor tyrosine kinase inhibitor)”, “abergastine α (third-generation long-acting G-CSF)”, “piamprizumab (anti-PD-1)” and “FS222 (PD-L1/CD137 double antibody)”, “bemosubimab (anti-PDL1)”, “TQB3617 (BET inhibitor)”, “TQB3728” IAP antagonists), “TQB2930 ( HER2 dual antibody)” will wait until 20
中國生物製藥：二零二三年年報
Sino Biopharm Completes Phase I Study of Hepatitis B Drug
Sino Biopharmaceutical (HKG:1177) said it recently successfully completed the phase I clinical study of its self-developed drug TQA3038 (siRNA), according to a Thursday filing with the Hong Kong Excha
Express News | China Biopharmaceutical: Class 1 innovative drug TQA3038 (siRNA has completed phase I clinical research
China Biopharmaceuticals (01177.HK) received 2 million additional shares from Chairman Xie Qirun
Gelonghui, April 24 | According to the latest equity disclosure data of the Stock Exchange, on April 23, 2024, China Biopharmaceutical (01177.HK) was granted an increase of 2 million shares at an average price of HK$2.5891 per share on the market, involving approximately HK$5.1782 million. After the increase in holdings, Xie Qirun's latest shareholding was 6 million shares, and the shareholding ratio increased from 0.02% to 0.03%.
The majority shareholders of Chinese biopharmaceuticals continued to increase their holdings, and the fund focused on increasing their holdings in the first quarter
China Biopharmaceutical (01177.HK) obtained Xie Qirun to increase its common shares by 2 million shares, worth approximately HK$5.178,200
On April 23, it was reported that according to the documents disclosed by the Hong Kong Stock Exchange on April 23, Xie Qirun increased its common share holdings of $China Biopharmaceutical (01177.HK) by $2 million at an average price of HK$2.5891 per share on April 23, worth about HK$5.178,200. After the increase in holdings, Xie Qirun's latest shareholding was 6 million shares, and the good position ratio increased from 0.02% to 0.03%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Listed public
Analysis
Price Target
No Data
